i3S is the largest research institute in Health and Life sciences in Portugal, resulting from a consortium between IPATIMUP, IBMC, INEB, and UPORTO. i3S researchers tackle major scientific questions in cancer, infectious diseases, and neurologic disorders, in multidisciplinary projects involving basic, translational, and clinical research. i3S has ~900 researchers, publishes ~800 papers a year, and has 31 active patents and 33 H2020 projects approved. i3S has protocols of scientific collaboration with six schools of UPorto and with three major hospitals, including Centro Hospitalar Universitário S. João (CHUSJ) and IPO-Porto. The Institute also has three diagnostics platforms that provide clinical services to the community.
i3S participates in multiple national and European scientific/infrastructure networks, including the National Network of Comprehensive Cancer Centres, the Portuguese Biological Data Network, the National Biobanks Infrastructure, the National Facility for Genome Sequencing and Analysis, the Health Cluster Portugal, and the European Strategy Forum on Research Infrastructures (ESFRI)-integrated infrastructures EU-OPENSCREEN ERIC, Euro-BioImaging, ELIXIR, Instruct-ERIC, Protein Production and Purification Partnership, European Technology Platform on Nanomedicine, and the European Advanced Translational Research Infrastructure in Medicine.
i3S has 13 technological platforms, providing access to cutting-edge equipment for research in several fields. The Institute has transversal units that assure all management, financial, and communications aspects to implement R&D projects. Finally, i3S fosters continuous advanced training for scientists and implements annual educational and outreach activities to close the gap between science and society.
The i3S team involved in AIDA has a successful collaborative history, being recognised for their major contributions to gastric cancer histopathology and classification, and to gastric carcinogenesis associated with H. pylori virulence factors and microbiome.